We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akouos, Inc. (“Akouos” or the “Company”) (NASDAQ:AKUS), in connection with the proposed tender offer for the Company by Eli Lilly and Company (NYSE: LLY).  Under the tender offer, the Company’s shareholders will receive $12.50 in cash, plus one contingent value right (“CVR”) of up to $3.00 per share for each share of Akouos common stock owned.

Weiss Law is investigating whether (i) Akouos’ board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $12.50 per-share merger consideration adequately compensates Akouos’ shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.  Notably, the merger consideration is below the $25 median price target set by analysts, and at least one analyst set a price target for the Company of $35 per share, $22.50 above the per-share merger consideration.